Cited 20 times in
Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신동아 | - |
dc.date.accessioned | 2018-07-20T12:02:25Z | - |
dc.date.available | 2018-07-20T12:02:25Z | - |
dc.date.issued | 2017 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/161678 | - |
dc.description.abstract | BACKGROUND: We examined the effectiveness and tolerability of transdermal buprenorphine (TDB) treatment in real-world setting in Asian patients with musculoskeletal pain. METHODS: This was an open-label study conducted in Hong Kong, Korea, and the Philippines between June 2013 and April 2015. Eligible patients fulfilled the following criteria: 18 to 80 years of age; clinical diagnosis of osteoarthritis, rheumatoid arthritis, low back pain, or joint/muscle pain; chronic non-malignant pain of moderate to severe intensity (Box-Scale-11 [BS-11] pain score ≥ 4), not adequately controlled with non-opioid analgesics and requiring an opioid for adequate analgesia; and no prior history of opioid treatment. Patients started with a 5 μg/h buprenorphine patch and were titrated as necessary to a maximum of 40 μg/h over a 6-week period to achieve optimal pain control. Patients continued treatment with the titrated dose for 11 weeks. The primary efficacy endpoint was the change in BS-11 pain scores. Other endpoints included patients' sleep quality and quality of life as assessed by the 8-item Global Sleep Quality Assessment Scale (GSQA) questionnaire and the EuroQol Group 5-Dimension Self-Report Questionnaire-3 Level version (EQ-5D-3 L), respectively. Tolerability was assessed by collecting adverse events. RESULTS: A total of 114 eligible patients were included in the analysis. The mean BS-11 score at baseline was 6.2 (SD 1.6). Following initiation of TDB, there was a statistically significant improvement in BS-11 score from baseline to visit 3 (least squares [LS] mean change: -2.27 [95% CI -2.66 to -1.87]), which was maintained till the end of the study (visit 7) (LS mean change: -2.64 [95% -3.05 to -2.23]) (p < 0.0001 for both). The proportion of patients who rated sleep quality as 'good' increased from 14.0% at baseline to 26.9% at visit 6. By visit 6, the mean EQ VAS score increased by 7.7 units (SD 17.9). There were also significant improvements in patients' levels of functioning for all EQ-5D-3 L dimensions from baseline at visit 6 (p < 0.05 for all). Seventy-eight percent of patients reported TEAEs and 22.8% of patients discontinued due to TEAEs. TEAEs were generally mild to moderate in intensity (96.5%). CONCLUSIONS: TDB provides effective pain relief with an acceptable tolerability profile over the 11-week treatment period in Asian patients with chronic musculoskeletal pain. More studies are needed to examine the long-term efficacy and safety of TBD treatment in this patient population. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | BioMed Central | - |
dc.relation.isPartOf | BMC MUSCULOSKELETAL DISORDERS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Administration, Cutaneous | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Analgesics, Opioid/therapeutic use* | - |
dc.subject.MESH | Buprenorphine/therapeutic use* | - |
dc.subject.MESH | Chronic Pain/drug therapy* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hong Kong | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Musculoskeletal Pain/drug therapy* | - |
dc.subject.MESH | Pain Management/methods | - |
dc.subject.MESH | Pain Measurement | - |
dc.subject.MESH | Philippines | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Quality of Life | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Surveys and Questionnaires | - |
dc.subject.MESH | Transdermal Patch/adverse effects* | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Neurosurgery | - |
dc.contributor.googleauthor | Do Heum Yoon | - |
dc.contributor.googleauthor | Seong-Il Bin | - |
dc.contributor.googleauthor | Simon Kin-Cheong Chan | - |
dc.contributor.googleauthor | Chun Kee Chung | - |
dc.contributor.googleauthor | Yong In | - |
dc.contributor.googleauthor | Hyoungmin Kim | - |
dc.contributor.googleauthor | Juan Javier Lichauco | - |
dc.contributor.googleauthor | Chi Chiu Mok | - |
dc.contributor.googleauthor | Young-Wan Moon | - |
dc.contributor.googleauthor | Tony Kwun-Tung Ng | - |
dc.contributor.googleauthor | Ester Gonzales Penserga | - |
dc.contributor.googleauthor | Dong Ah Shin | - |
dc.contributor.googleauthor | Dora You | - |
dc.contributor.googleauthor | Hanlim Moon | - |
dc.identifier.doi | 10.1186/s12891-017-1664-4 | - |
dc.contributor.localId | A02092 | - |
dc.relation.journalcode | J00366 | - |
dc.identifier.eissn | 1471-2474 | - |
dc.identifier.pmid | 28778219 | - |
dc.subject.keyword | Asian | - |
dc.subject.keyword | Chronic non-malignant pain | - |
dc.subject.keyword | Effectiveness | - |
dc.subject.keyword | Musculoskeletal | - |
dc.subject.keyword | Pain score | - |
dc.subject.keyword | Quality of life | - |
dc.subject.keyword | Sleep quality | - |
dc.subject.keyword | Tolerability | - |
dc.subject.keyword | Transdermal buprenorphine | - |
dc.contributor.alternativeName | Shin, Dong A | - |
dc.contributor.affiliatedAuthor | Shin, Dong A | - |
dc.citation.volume | 18 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 337 | - |
dc.identifier.bibliographicCitation | BMC MUSCULOSKELETAL DISORDERS, Vol.18(1) : 337, 2017 | - |
dc.identifier.rimsid | 61701 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.